Shamburg News · 8-K filed Oct 1, 2026, 9:16 AM EDT
Gain Therapeutics Presents Long-Term Rexaceract Parkinson's Open-Label Extension Data
GANX · Gain Therapeutics, Inc.
- Other event
- Materiality: medium
On October 1, 2026, Gain Therapeutics, Inc. announced a poster presentation at the International Congress of Parkinson's Disease and Movement Disorders in Seoul, October 4-8, 2026, on long-term open-label extension data for rexaceract. The filing states that MDS-UPDRS motor scores were stable over 12 months of dosing in 12 evaluable participants, with safety data showing a lower incidence of treatment-emergent adverse events in the nine-month extension than in the initial three-month period. The Company expects to submit a new Phase 2 protocol to the FDA in the coming weeks and initiate the Phase 2 trial in the first quarter of 2027.
Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001104659-26-112624.
Written from the filing by Shamburg Markets. Figures are as reported by the company.